Cocrystal Pharma Reports Q3 GAAP EPS of -$0.20 and Revenue of $0.11 Million
Cocrystal Pharma (COCP) has released its third-quarter financial results, reporting a GAAP earnings per share (EPS) loss of $0.20. The company's revenue for the period reached $0.11 million. The report reflects the ongoing early-stage nature of the company's operations as it continues to navigate its current fiscal cycle. Investors are monitoring these figures for indications of cash burn and progress toward future commercialization milestones.

Tickers: $COCP
Topics: earnings GAAP EPS revenue
Read the full article at Seeking Alpha
Part of the story American Fusion Inc. Reports Third Quarter Net Loss of $1.44 Million (3 articles)